Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.64 HKD | -1.02% | +3.93% | +15.02% |
May. 13 | China Life Insurance’s Premium Income Up 4% in January-April | MT |
May. 08 | Nomura Adjusts China Life Insurance’s Price Target to 17.80 Yuan From 17.57 Yuan, Keeps at Reduce | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company appears to be poorly valued given its net asset value.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.02% | 102B | B- | ||
+5.83% | 102B | B | ||
-7.57% | 92.29B | B+ | ||
+11.83% | 67.53B | D+ | ||
+16.65% | 33.36B | B | ||
+10.34% | 28.7B | A | ||
+18.30% | 28.68B | B | ||
+0.02% | 17.09B | C+ | ||
-13.17% | 14.41B | B | ||
+25.48% | 13.54B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 2628 Stock
- Ratings China Life Insurance Company Limited